Cancer Research UK Teams Up with London Startup in Immuno-oncology

Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors.

There will (probably) be a new immuno-oncology drug on the block soon: Cancer Research UK has gone in on London startup Biotecnol‘s antibody in a deal to bring it to an open-label Phase I trial. The drug, Tb535H, is designed to bind to and flag the 5T4/WAIF1 tumor antigen for attack by CD8-positive T cells.

This approach is well-established in immuno-oncology — another English biotech, Scancell, has reached gold-standard survival with its CD8-activating vaccine, and Stimunity in Paris is working along the same lines — but leveraging this antigen is unique to the Biotecnol. In fact, the WAIF1 antigen was discovered by CRUK as having a role in cancers with solid tumors, including those in the lungs, making the partnership a natural choice.

Image via UGREEN 3S /

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.